论文部分内容阅读
目的:观察川芎嗪注射液改善腹透患者超滤功能及腹膜纤维化的临床效果,并探讨不同给药方式对改善程度的影响。方法:采用随机分组对照的方法将60例腹透患者分为常规对照组(A组)、静脉注射组(B组)、腹腔给药组(C组),各20例,观察3组Kt/V,Ccr、超滤量、溶质转运参数等指标的变化。结果:B组与C组超滤量治疗前后组内比较及各组治疗后两两比较,差异均有统计学意义(P<0.05)。3组尿量治疗前后组内比较及组间比较,差异无统计学意义(P>0.05)。B组与C组Kt/V、Ccr/Pcr治疗前后组内比较,差异有统计学意义(P<0.05);而A组治疗前后比较,差异无统计学意义(P>0.05)。3组血压及生化指标治疗前后组内比较,差异均无统计学意义(P>0.05)。结论:川芎嗪注射液进行腹腔给药,可在不增加患者水负荷的基础上,增加超滤量,提高透析充分性,有效缓解患者腹膜纤维化程度。
OBJECTIVE: To observe the clinical effect of ligustrazine injection on the improvement of ultrafiltration and peritoneal fibrosis in patients with peritoneal dialysis and to explore the effect of different administration modes on the improvement. Methods: Sixty patients with peritoneal dialysis were randomly divided into two groups: control group (A), intravenous injection group (B) and intraperitoneal injection group (C) V, Ccr, ultrafiltration volume, solute transport parameters and other indicators of change. Results: The ultrafiltration volume in group B and group C before and after treatment was compared with each group after treatment, and the difference was statistically significant (P <0.05). Three groups before and after treatment of urine volume comparison and between groups, the difference was not statistically significant (P> 0.05). The difference was statistically significant (P <0.05) between group B and group C before and after Kt / V and Ccr / Pcr treatment, while there was no significant difference between group A and group C before and after treatment (P> 0.05). There was no significant difference in blood pressure and biochemical indexes between the three groups before and after treatment (P> 0.05). Conclusion: Ligustrazine injection for intraperitoneal administration can increase the amount of ultrafiltration, increase the adequacy of dialysis and relieve peritoneal fibrosis in patients without increasing the water load of patients.